s 16020-2 has been researched along with Carcinoma, Lewis Lung in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Atassi, G; Genissel, P; Goldstein, S; Guilbaud, N; Guillonneau, C; Kraus-Berthier, L; Léonce, S; Parker, T; Pierré, A | 1 |
Atassi, G; Bisagni, E; Burbridge, M; Guilbaud, N; Jan, M; Kraus-Berthier, L; Pierré, A; Rouillon, MH; Saint-Dizier, D; Visalli, M | 1 |
Atassi, G; Burbridge, M; Guilbaud, N; Jan, M; Kraus-Berthier, L; Pierré, A; Rouillon, MH; Saint-Dizier, D | 1 |
3 other study(ies) available for s 16020-2 and Carcinoma, Lewis Lung
Article | Year |
---|---|
Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Topics: Adenocarcinoma; Animals; Animals, Congenic; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Drug Screening Assays, Antitumor; Ellipticines; Enzyme Inhibitors; Female; Humans; Leukemia P388; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Nude; Mice, SCID; Neoplasm Proteins; Organ Specificity; Ovarian Neoplasms; Prodrugs; Prostatic Neoplasms; Topoisomerase II Inhibitors; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2002 |
In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Blood Cell Count; Bone Marrow; Breast Neoplasms; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Ellipticines; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Leukemia P388; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Tumor Cells, Cultured | 1996 |
Antitumor activity of S 16020-2 in two orthotopic models of lung cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Cyclophosphamide; Ellipticines; Humans; Longevity; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Survival; Transplantation, Heterologous | 1997 |